Results 71 to 80 of about 34,497 (254)
, 2022 20.500.12530/87858Spironolactone when combined with abiraterone in metastatic castration-resistant prostate cancer (mCRPC) may theoretically exert androgenic properties, thereby compromising the therapeutic effectiveness of abiraterone. Two patients with
Vicente-Valor, Juan +19 more
core +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
ESC Heart Failure, 2020 Aims Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients ...
Nobuyuki Enzan +6 more
doaj +1 more source
Spironolactone: A selective androgen receptor modulator in castration-resistant prostate cancer.
, 2014 212 Background: Spironolactone is an effective drug to treat arterial hypertension as well as fluid retention and hypokalemia. Recently, some data suggested that spironolactone might induce progression in castration-resistant prostate cancer (CRPC ...
Philippe Barthelemy +11 more
core +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
International Journal of Gynecology &Obstetrics, EarlyView.Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto +9 more
wiley +1 more source
PLoS ONEPurposeThe correlation between spironolactone usage and cancer risk has sparked interest. The objective of this study is to examine the association between spironolactone use and the incidence of urinary tract cancer in the general population.MethodsWe ...
Liang-Cheng Chen +9 more
doaj +1 more source
Spironolactone Management of Resistant Hypertension
, 2010 Objective: To review the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and adverse effects of spironolactone in the treatment of resistant hypertension.
Joel C Marrs
core +1 more source
Spironolactone and colitis: Increased mortality in rodents and in humans [PDF]
, 2012 Background: Crohn's disease causes intestinal inflammation leading to intestinal fibrosis. Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality. We examined whether spironolactone is antifibrotic in the context
Higgins, Peter D.R. +11 more
core +1 more source
The association between spironolactone exposure and risk of upper urinary tract cancers among different groups of spironolactone use.
Moon-Sing Lee (417997) +9 more
core +1 more source